Literature DB >> 20193764

Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.

Dimitris Repantis1, Oona Laisney, Isabella Heuser.   

Abstract

The term neuroenhancement refers to improvement in the cognitive, emotional and motivational functions of healthy individuals through, inter alia, the use of drugs. Of known interventions, psychopharmacology provides readily available options, such as the anti-dementia drugs, e.g. acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. Based on a systematic review we found that expectations about the potential of these drugs exceed their actual effects, as has been demonstrated in randomised controlled trials. Both single and repeated dose trials were included in the systematic review, however repeated dose trials have only been conducted for donepezil. In six small trials lasting 14-42 days, the following results emerged: donepezil improved the retention of training on complex aviation tasks and verbal memory for semantically processed words. In one study episodic memory was improved, whereas in others it remained unaffected by donepezil. In a sleep deprivation trial, donepezil reduced the memory and attention deficits resulting from 24h of sleep deprivation. Two studies reported even transient negative effects. Regarding the safety profile of donepezil, these studies found that it was rather well tolerated. In any case, since large longitudinal studies are not available no conclusions can be drawn. Seven small studies about the effects of a single dose of memantine, and one study with a single dose of rivastigmine have been reported. Again, these studies are not adequate to answer our research question. If, as here and elsewhere suggested, the concept of pharmaceutical neuroenhancement is not to be rejected in principle, the decision of healthy individuals to take drugs for the purpose of neuroenhancement should be based on exhaustive information. At the moment, the research that would support or oppose the use of acetylcholinesterase inhibitors and memantine for neuroenhancement by healthy individuals has not yet been performed. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193764     DOI: 10.1016/j.phrs.2010.02.009

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  41 in total

1.  The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

Authors:  Derek S Wilkinson; Thomas J Gould
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

2.  Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis.

Authors:  L B Krupp; C Christodoulou; P Melville; W F Scherl; L-Y Pai; L R Muenz; D He; R H B Benedict; A Goodman; S Rizvi; S R Schwid; B Weinstock-Guttman; H J Westervelt; H Wishart
Journal:  Neurology       Date:  2011-04-26       Impact factor: 9.910

3.  Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study.

Authors:  Jon E Grant; Samuel R Chamberlain; Brian L Odlaug; Marc N Potenza; Suck Won Kim
Journal:  Psychopharmacology (Berl)       Date:  2010-08-19       Impact factor: 4.530

4.  Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study.

Authors:  Rebecca L Ashare; Riju Ray; Caryn Lerman; Andrew A Strasser
Journal:  Drug Alcohol Depend       Date:  2012-05-15       Impact factor: 4.492

5.  Cosmetic neurology: the role of healthcare professionals.

Authors:  Kinan Muhammed
Journal:  Med Health Care Philos       Date:  2014-05

Review 6.  A compensatory role for declarative memory in neurodevelopmental disorders.

Authors:  Michael T Ullman; Mariel Y Pullman
Journal:  Neurosci Biobehav Rev       Date:  2015-01-15       Impact factor: 8.989

Review 7.  Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.

Authors:  L-S Camilla d'Angelo; George Savulich; Barbara J Sahakian
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

8.  Should physicians prescribe cognitive enhancers to healthy individuals?

Authors:  Cynthia Forlini; Serge Gauthier; Eric Racine
Journal:  CMAJ       Date:  2012-12-17       Impact factor: 8.262

9.  Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals.

Authors:  Cynthia Forlini; Wayne Hall; Bruce Maxwell; Simon M Outram; Peter B Reiner; Dimitris Repantis; Maartje Schermer; Eric Racine
Journal:  EMBO Rep       Date:  2013-01-15       Impact factor: 8.807

10.  The value and pitfalls of speculation about science and technology in bioethics: the case of cognitive enhancement.

Authors:  Eric Racine; Tristana Martin Rubio; Jennifer Chandler; Cynthia Forlini; Jayne Lucke
Journal:  Med Health Care Philos       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.